Medicines Company (MNMD) all U.S. Lobbying: all historical lobbying contracts, government bills & agencies, and critical issues lobbied on.

$99.95

Discover Medicines Company’s lobbying activities with our comprehensive dataset, offering insights on spending, bills, and issues from 1999-present. Analyze data by company, lobbyist, issue, and more through our intelligently crafted data design. Dataset updated weekly.

Description

Using our intelligently designed and intuitive dataset, you can quickly understand how Medicines Company (MNMD) is lobbying the U.S. government, how much they’re spending on it, and most importantly – the bills and specific issues on which they lobby.

Gain an informational edge with our Lobbying Data Intelligence. Perform analysis by company, lobbyist, lobbying firm, government agency, or issue.

For lobbying firms: understand your competitors. Understand who is registering with who. Gain insight on quarterly reports and specific issues other firms are lobbying on.

Our lobbying data is collected and aggregated from the U.S. Senate Office of Public Records from 1999-present and is updated on a regular basis. We utilize advanced data science techniques to ensure accurate data points are collected and ingested, match similar entities across time, and tickerize publicly traded companies that lobby.

Our comprehensive and advanced lobbying database is completed with all the information you need, with more than 1.6 million lobbying contracts ready-for-analysis. We include detailed information on all aspects of federal lobbying, including the following fascinating attributes, among much more:

1. Clients: The publicly traded company, privately owned company, interest group, NGO, or state or local government that employs or retains a lobbyist or lobbying firm.

2. Registrants (Lobbying Firms): Either the name of the lobbying firm hired by the client, or the name of the client if the client employs in-house lobbyists.

3. Lobbyists: The names and past government work experience of the individual lobbyists working on a lobbying contract. 3. General Issues: The general issues for which clients lobby on (ex: ENV – Environment, TOB – Tobacco, FAM – Family Issues/Abortion).

4. Specific Issues: A long text description of the exact bills and specific issues for which clients lobby on.

5. Bills Lobbied On: The exact congressional bills and public/private laws lobbied on, parsed from lobbying report specific issues (ex: H.R. 2347, S. 1117, Tax Cuts and Jobs Act).

6. Agencies Lobbied: The names of one or more of 250+ government agencies lobbied on in the contract (ex: White House, FDA, DOD).

7. Foreign Entities: The names and origin countries of entities affiliated with the client (ex: BNP Paribas: France).

Gain access to our highly unique and actionable U.S. lobbying database. Further information on LobbyingData.com and our alternative datasets and database can be found on our website, or by contacting [email protected].

Frequently Asked Questions

What is Medicines Company (MNMD) lobbying for?

Summary of Medicines Company Lobbying Data:
– Lobbying Firms: Gibbons P.C., Squire Patton Boggs
– General Issues: Copyright/Patent/Trademark
– Specific Issues: Intellectual property; issues related to Director of the US Patent & Trademark Office accepting late filings in certain cases of unintentional delay
– Government Agencies: Senate, House of Representatives

One could infer that Medicines Company is lobbying on patent and trademark issues related to intellectual property in order to protect their own patents and trademarks, possibly in response to competitors attempting to infringe upon them or disputes over licensing agreements. The specific issue related to late patent filings may indicate that the company experienced difficulties in submitting timely patent applications or encountered conflicts with the US Patent & Trademark Office in the past. By lobbying government agencies, they aim to influence policies and decisions that could affect the company’s intellectual property rights and legal disputes.

Subscribe To Our Newsletter

gain actionable insights from our alternative data

More to explore